



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	09/622,452
Filing Date	October 31, 2000
First Named Inventor	David B. Weiner
Art Unit	1633
Examiner Name	Anne Marie S Wehbe
Attorney Docket Number	UPAP0011-100

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
AW ↓	1	US-5,962,428	10-05-1999	Carrano et al.	
	2	US-5,739,118	04-14-1998	Carrano et al.	
	3	US-6,197,755	03-06-2001	Carrano et al.	
	4	US-6,417,328	07-09-2002	Alnemri	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
AW ↓	5	WO 99/43839	09-02-1999	University of Penn		
	6	WO 96/26285	08-29-1996	University of Penn		
	7	WO 96/40267	12-19-1996	Whitehead Inst.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

### Complete if Known

Application Number	09/622,452
Filing Date	October 31, 2000
First Named Inventor	David B. Weiner
Art Unit	1633
Examiner Name	Anne Marie S. Wehbe
Attorney Docket Number	UPAP0011-100

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AW	8	Caamaño, et al., "Nuclear Factor (NF)- $\kappa$ B2 (p100/p52) is Required for Normal Splenic Microarchitecture and B Cell-mediated Immune Responses," <i>The Journal of Experimental Medicine</i> , (1998) 187(2):185-196.	
	9	Chattergoon, et al., "Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis," <i>Nature Biotechnology</i> (2000) 18:974-979.	
	10	Chattergoon, et al., "DR5 triggered apoptosis functions as a vaccine adjuvant by inducing caspase-8 dependent dendritic cell maturation," (27 pp.)	
	11	Chaudhary, et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent apoptosis and Activate the NF- $\kappa$ B Pathway," <i>Immunity</i> (1997) 7:821-830.	
	12	Chow et al., "Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes," <i>J Immunol</i> (1988) 140(4):1320-1329.	
	13	Denich, et al., "Expression of the Murine Interleukin-4 Gene in an Attenuated aroA Strain of <i>Salmonella typhimurium</i> : Persistence and Immune Response in BALB/c Mice and Susceptibility to Macrophage Killing," <i>Infection and Immunity</i> , (1993) 61(11):4818-4827	
	14	Geissler et al., "Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids," <i>J Immunol</i> (1997) 158(3):1231-7.	
	15	Iwasaki et al., "Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines," <i>J Immunol</i> (1997) 158(10):4591-4601.	
	16	Ramshaw et al., "Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo," <i>Immunol Rev</i> (1992) 127:157-178.	
	17	Sha, "Regulation of Immune Responses by NF- $\kappa$ B/Rel Transcription Factors," <i>J Exp Med</i> (1998) 187(2):143-146	
✓	18	Schneider, et al., "TRAIL Receptors 1 (DR4) and 2 (DR5) Signal FADD-Dependent Apoptosis and Activate NF- $\kappa$ B," <i>Immunity</i> (1997) 7:831-836	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/622,452
		Filing Date	October 31, 2000
		First Named Inventor	David B. Weiner
		Art Unit	1633
		Examiner Name	Anne Marie S. Wehbe
		Attorney Docket Number	UPAP0011-100
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AW	19	Tsuji et al., "HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine," <i>Immunology</i> (1997) 90:1-6.	
	20	Xiang et al., "Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines," <i>Immunity</i> (1995) 2(2):129-135.	
	21	Goya, Inigo et al., "Identification of CCR8 as the Specific Receptor for the Human $\beta$ -Chemokine I-309: Cloning and Molecular Characterization of Murine CCR8 as the Receptor for TCA-3 <sup>1</sup> ", <i>J. Immunol.</i> , 1998, 160: 1975-1981.	
	22	Kuna, P. et al., "Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family", <i>J. Immunol.</i> 1993 Mar 1; 150(5): 1932-43.	
	23	Lee, Tiffany et al., "Identification of CCR8: A Human Monocyte and Thymus Receptor for the CC Chemokine I-309", <i>J. Exp. Med.</i> 186(1), July 1997, 165-170.	
	24	Paolini, J.F. et al., "The chemokines IL-8, monocyte chemoattractant protein-1, and I-309 are monomers at physiologically relevant concentrations", <i>J. Immunol.</i> 1994 Sep 15; 153(6): 2704-17.	
	25	Struber Roos, Regula et al., "Identification of CCR8, the Receptor for the Human CC Chemokine I-309", <i>Am. Soc. Biochem. &amp; Mol. Biol.</i> 272(28) July 1997, 17251-17254.	
	26	Van Snick, J. et al., "I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis", <i>J. Immunol.</i> 1996 Sep 15; 157(6):2570-6.	
↓	27	Misfeldt "Microbial 'Superantigens,'" <i>Infection and Immunity</i> (1990) 58(8):2409-2413.	

Examiner Signature	/Anne Marie Wehbe/ (01/06/2007)	Date Considered	01/06/2007
-----------------------	---------------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.